Background: Factors limiting the efficacy of conventional antiretroviral therapy for HIV-1
infection include treatment adherence, pharmacokinetics and penetration into viral …

Context Long-term antiretroviral therapy (ART) use in resource-limited countries leads to
increasing numbers of patients with HIV taking second-line therapy. Limited access to further …

The past decade has seen remarkable progress in increasing access to antiretroviral
therapy in resource-limited settings. Early concerns about the cost and complexity of …

Context Depression strongly predicts nonadherence to human immunodeficiency virus (HIV)
antiretroviral therapy, and adherence is essential to maintaining viral suppression. This …

Background Though the initiation of Highly Active Antiretroviral Therapy (HAART) has led to
decreased HIV/AIDS related mortality, the regimen has been reported to be associated with …

Objective: To identify risk factors associated with kidney function decline in a contemporary
cohort of treated and untreated HIV-infected patients. Methods: We followed individuals …

Background Maraviroc, a CCR5 antagonist, is active against R5 but not X4 or dual-or mixed-
tropic strains of human immunodeficiency virus type 1 (HIV-1). A phase 2b study was …

The introduction of highly active antiretroviral therapy (HAART) as standard of care has
changed the natural history of HIV infection into a manageable chronic disease requiring …

Human immunodeficiency virus (HIV) infection is now recognized as a chronic illness.
Although the success of highly active antiretroviral therapy is beyond question, several …

Background In the MONotherapy in Europe with Tmc114 (MONET) trial, darunavir/ritonavir
(DRV/r) monotherapy showed noninferior efficacy vs. two nucleoside reverse transcriptase …